RSV vaccine from GSK shows potential to protect adults 50 to 59
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial results suggest that GSK’s shot, known as Arexvy, could help protect a wider population from RSV, … Read more